Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab

摘要

IMPORTANCE Despite the increased use of rituximab therapy in neuromyelitis optica spectrum disorder (NMOSD), the overall efficacy and safety of long-term rituximab treatment in a large group of patients is uncertain. Furthermore, the identification of a predictor of rituximab response is an important issue for assessing the individual risk-benefit of therapy and making treatment decisions.